MedTrace Logo

Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 Years

NCT00546988 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2007-10-19

No results posted yet for this study

Summary

The study is evaluating whether risk-stratification by the means of a chromosomal aberration provides a tool to discriminate between standard and high risk. Risk-adapted therapy is based on allogeneic stem-cell transplantation for high-risk subjects instead of a second autograft in patients with deletion of chromosome 13 who have an HLA-identical stem cell donor available.

Conditions

Interventions

BIOLOGICAL

allogeneic stem cell transplant

Sponsors & Collaborators

  • University of Wuerzburg

    lead OTHER

Principal Investigators

  • Hermann Einsele, M.D. · Wuerzburg University Hospital, Dept. of Hematology and Oncology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-10-31
Completion
2008-01-31

Countries

  • Austria
  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00546988 on ClinicalTrials.gov